http://blog.pharmexec.com/2009/06/03/latest-news-from-asco/ The Business of Pharmaceuticals Wed, 08 Feb 2012 14:53:10 -0500 hourly 1 http://blog.pharmexec.com/2009/06/03/latest-news-from-asco/comment-page-1/#comment-107093 PI3 Kinase inhibitors – a report from ASCO | Pharma Strategy Blog Sun, 06 Mar 2011 13:22:27 +0000 http://blog.pharmexec.com/?p=797#comment-107093 [...] Latest News from ASCO: Winners, Losers, and Also Rans (pharmexec.com) [...] [...] Latest News from ASCO: Winners, Losers, and Also Rans (pharmexec.com) [...]

]]> http://blog.pharmexec.com/2009/06/03/latest-news-from-asco/comment-page-1/#comment-33226 Maen Addassi Thu, 04 Jun 2009 06:47:58 +0000 http://blog.pharmexec.com/?p=797#comment-33226 I think the Avastin is a big bubble should be finished for example: 1. Colorectal Cancer: with Oxaliplatin was not impressive. Only with Irinotecan also a negative result in early cancer 2. Breast cancer with old product called Paclitaxel was given a good result (only progression free survival not overall survival) but in the other hand with the newest & most common drug Docetaxel with a trial called Avado trial ; it seems the result was not so impressive they tried to promoted the Hazard ratio rather than a clinical result. The median time to disease progression was 8 months with docetaxel alone, compared with 8.7 months with docetaxel plus low-dose bevacizumab, and 8.8 months with docetaxel plus high-dose Bevacizumab it is 0.8 months = 24 days !!! 3. Lung cancer : at the beginning with Paclitaxel it was made a good survival a trial called E4599 by A Sandler published at 2006 at NEJM it is add 2 months for overall survival (from 10.2 to 12.2 ) with a double dose and of course a double cost. And at ATLAS study with Tarceva 1.3 Month more !!! 4. Renal cell carcinoma : same story; without any advantages regarding survival Kindly note the British health system was refused Avastin for CRC or other indications due to lack cost effectiveness Is it worth this!!! I think the Avastin is a big bubble should be finished for example:
1. Colorectal Cancer: with Oxaliplatin was not impressive. Only with Irinotecan also a negative result in early cancer
2. Breast cancer with old product called Paclitaxel was given a good result (only progression free survival not overall survival) but in the other hand with the newest & most common drug Docetaxel with a trial called Avado trial ; it seems the result was not so impressive they tried to promoted the Hazard ratio rather than a clinical result. The median time to disease progression was 8 months with docetaxel alone, compared with 8.7 months with docetaxel plus low-dose bevacizumab, and 8.8 months with docetaxel plus high-dose Bevacizumab it is 0.8 months = 24 days !!!
3. Lung cancer : at the beginning with Paclitaxel it was made a good survival a trial called E4599 by A Sandler published at 2006 at NEJM it is add 2 months for overall survival (from 10.2 to 12.2 ) with a double dose and of course a double cost. And at ATLAS study with Tarceva 1.3 Month more !!!
4. Renal cell carcinoma : same story; without any advantages regarding survival
Kindly note the British health system was refused Avastin for CRC or other indications due to lack cost effectiveness
Is it worth this!!!

]]>